Treatment with Botulinum Neurotoxin Improves Activities of Daily Living and Quality of Life in Patients with Upper Limb Tremor.
Activities of Daily Living
Adolescent
Adult
Aged
Aged, 80 and over
Botulinum Toxins, Type A
/ therapeutic use
Child
Female
Humans
Male
Middle Aged
Neuromuscular Agents
/ therapeutic use
Parkinson Disease
/ drug therapy
Treatment Outcome
Tremor
/ drug therapy
Upper Extremity
/ physiopathology
Young Adult
Clinical Global Impression
activities of daily living
botulinum neurotoxin
quality of life
upper limb tremor
Journal
Tremor and other hyperkinetic movements (New York, N.Y.)
ISSN: 2160-8288
Titre abrégé: Tremor Other Hyperkinet Mov (N Y)
Pays: England
ID NLM: 101569493
Informations de publication
Date de publication:
2019
2019
Historique:
received:
22
01
2019
accepted:
14
06
2019
entrez:
16
8
2019
pubmed:
16
8
2019
medline:
29
1
2020
Statut:
epublish
Résumé
Botulinum neurotoxin's degree of effectiveness on upper limb tremor is subject to debate; although this treatment reduces the tremor's amplitude, a clear functional benefit has not been demonstrated. The objective of this study was to assess the effect of botulinum neurotoxin type A treatment on activities of daily living and quality of life in patients with upper limb tremor. We retrospectively examined the medical records of 50 consecutive patients treated with botulinum neurotoxin for upper limb tremor that was refractory to oral medication. One month after the injection, the patient was evaluated according to the Quality of Life in Essential Tremor Questionnaire, and the Essential Tremor Embarrassment Assessment. Full data sets were available for 38 patients suffering variously from essential tremor ( Botulinum neurotoxin treatment of patients with upper limb tremor is associated with improved quality of life and activities of daily living, irrespective of the tremor's etiology. Long-term treatment enables the physician to adjust the injection strategy to the patient's needs. Our study was limited by its retrospective design. The results must therefore be confirmed in a prospective, double-blind, placebo-controlled, randomized clinical trial.
Sections du résumé
Background
Botulinum neurotoxin's degree of effectiveness on upper limb tremor is subject to debate; although this treatment reduces the tremor's amplitude, a clear functional benefit has not been demonstrated. The objective of this study was to assess the effect of botulinum neurotoxin type A treatment on activities of daily living and quality of life in patients with upper limb tremor.
Methods
We retrospectively examined the medical records of 50 consecutive patients treated with botulinum neurotoxin for upper limb tremor that was refractory to oral medication. One month after the injection, the patient was evaluated according to the Quality of Life in Essential Tremor Questionnaire, and the Essential Tremor Embarrassment Assessment.
Results
Full data sets were available for 38 patients suffering variously from essential tremor (
Discussion
Botulinum neurotoxin treatment of patients with upper limb tremor is associated with improved quality of life and activities of daily living, irrespective of the tremor's etiology. Long-term treatment enables the physician to adjust the injection strategy to the patient's needs. Our study was limited by its retrospective design. The results must therefore be confirmed in a prospective, double-blind, placebo-controlled, randomized clinical trial.
Identifiants
pubmed: 31413896
doi: 10.7916/tohm.v0.640
pii: tre-09-640
pmc: PMC6691906
doi:
Substances chimiques
Neuromuscular Agents
0
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
Funding: None. Conflicts of Interest: The authors report no conflict of interest. Ethics Statement: This study was performed in accordance with the ethical standards detailed in the Declaration of Helsinki. The authors’ institutional ethics committee has approved this study and all patients have provided written informed consent.
Références
J Neurosurg. 2014 May;120(5):1025-32
pubmed: 24605838
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S171-5
pubmed: 26382842
Mov Disord. 2014 May;29(6):835-8
pubmed: 24519658
Parkinsonism Relat Disord. 2018 Nov;56:65-69
pubmed: 29929813
Mov Disord. 1996 May;11(3):250-6
pubmed: 8723140
Expert Rev Neurother. 2016 Aug;16(8):983-97
pubmed: 27228280
Neurology. 2015 Nov 3;85(18):1562-8
pubmed: 26446066
PLoS One. 2017 Jun 6;12(6):e0178670
pubmed: 28586370
Mov Disord. 2018 Jan;33(1):75-87
pubmed: 29193359
Eur J Neurol. 2006 Nov;13(11):1186-202
pubmed: 17038032
J Neurol. 2013 Mar;260(3):714-40
pubmed: 22886006
Surg Neurol. 1998 Feb;49(2):145-53; discussion 153-4
pubmed: 9457264
Tremor Other Hyperkinet Mov (N Y). 2015 Oct 30;5:348
pubmed: 26566459
Parkinsonism Relat Disord. 2005 Sep;11(6):367-73
pubmed: 16103000
Neurology. 2001 Jun 12;56(11):1523-8
pubmed: 11402109
Mayo Clin Proc. 2017 Sep;92(9):1359-1367
pubmed: 28789780
Parkinsonism Relat Disord. 2015 Jul;21(7):729-35
pubmed: 25952960
Neurol Sci. 2000 Dec;21(6):349-53
pubmed: 11441571
Parkinsonism Relat Disord. 2010 Nov;16(9):561-5
pubmed: 20630791
Neurology. 1989 Dec;39(12):1587-8
pubmed: 2586774
Eur Neurol. 1996;36(1):29-35
pubmed: 8719647
Can J Neurol Sci. 2013 Sep;40(5):663-9
pubmed: 23968939
Neurology. 2011 Nov 8;77(19):1752-5
pubmed: 22013182
Parkinsonism Relat Disord. 2010 Dec;16(10):661-5
pubmed: 20869901
Parkinsonism Relat Disord. 2016 Aug;29:3-9
pubmed: 27062584
J Neurol Neurosurg Psychiatry. 2008 May;79(5):504-13
pubmed: 18037630
Neurology. 2016 Mar 8;86(10):931-8
pubmed: 26865524
PLoS One. 2017 Jul 5;12(7):e0178984
pubmed: 28678830
Can J Neurol Sci. 2018 Jan;45(1):11-22
pubmed: 29157315
PLoS One. 2016 Apr 21;11(4):e0153739
pubmed: 27101283
Mov Disord. 2010 Apr 15;25(5):534-41
pubmed: 20175185
J Cent Nerv Syst Dis. 2014 Apr 21;6:29-39
pubmed: 24812533
Toxins (Basel). 2018 Jul 19;10(7):
pubmed: 30029483